RESUMEN
OBJECTIVE: Apoptosis of cardiomyocytes may contribute to ischemia-reperfusion injury. The role of nitric oxide (NO) in apoptosis is controversial. Therefore, we investigated the effect of NO synthase inhibition on apoptosis of cardiomyocytes during ischemia and reperfusion and elucidated the underlying mechanisms. METHODS AND RESULTS: Isolated perfused rat hearts (n = 6/group) were subjected to ischemia (30 min) and reperfusion (30 min) in the presence or absence of the NO synthase inhibitor NG-mono-methyl-L-arginine. Reperfusion induced cardiomyocyte apoptosis as assessed by immunohistochemistry (TUNEL-staining) and the demonstration of the typical DNA laddering. Apoptosis during reperfusion was associated with the cleavage of caspase-3, the final down-stream executioner caspase, whereas the protein levels of the anti-apoptotic protein Bcl-2 and the pro-apoptotic protein Bax were unchanged. Inhibition of the NO synthase drastically increased ischemia and reperfusion-induced apoptosis of cardiomyocytes. Moreover, the NO synthase inhibitor enhanced the activation of caspase-3, suggesting that NO interferes with the activation of caspases in ischemia-reperfusion. CONCLUSION: The results of the present study demonstrate that inhibition of endogenous NO synthesis during ischemia and reperfusion leads to an enhanced induction of apoptosis, suggesting that the endogenous NO synthesis protects against apoptotic cell death. Inhibition of NO synthesis thereby activates the caspase cascade, whereas the Bcl-2/Bax protein levels remained unchanged.
Asunto(s)
Apoptosis/efectos de los fármacos , Caspasas/metabolismo , Daño por Reperfusión Miocárdica/enzimología , Miocardio/enzimología , Óxido Nítrico Sintasa/antagonistas & inhibidores , Transducción de Señal , omega-N-Metilarginina/farmacología , Análisis de Varianza , Animales , Western Blotting , Caspasa 3 , Células Cultivadas , Activación Enzimática , Etiquetado Corte-Fin in Situ , Masculino , Daño por Reperfusión Miocárdica/metabolismo , Miocardio/metabolismo , Proteínas Proto-Oncogénicas/metabolismo , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Ratas , Ratas Wistar , Proteína X Asociada a bcl-2RESUMEN
OBJECTIVE: The aim was to characterise the new compound HOE642 as a selective and cardioprotective Na+/H+ exchange inhibitor in various models. METHODS: The effect of HOE642 was tested in the osmotically activated Na+/H+ exchange of rabbit erythrocytes and in propionate induced swelling of human thrombocytes. Recovery of pH after an NH4Cl prepulse and effects on other ion transport systems by patch clamp technique were investigated in rat cardiomyocytes. NHE subtype specifity of the compound was determined by 22Na+ uptake inhibition in a fibroblast cell line separately expressing subtype isoforms 1-3. Protective effects of HOE642 in cardiac ischaemia and reperfusion by ligation of coronary artery were investigated in isolated working rat hearts and in anaesthetised rats. RESULTS: HOE642 concentration dependently inhibited the amiloride sensitive sodium influx in rabbit erythrocytes, reduced the swelling of human platelets induced by intracellular acidification, and delayed pH recovery in rat cardiomyocytes. In the isolated working rat heart subjected to ischaemia and reperfusion HOE642 dose dependently reduced the incidence and the duration of reperfusion arrhythmias. It also reduced the the release of lactate dehydrogenase and creatine kinase, and preserved the tissue content of glycogen, ATP, and creatine phosphate. In anaesthetised rats undergoing coronary artery ligation intravenous and oral pretreatment with HOE642 caused a dose dependent reduction or a complete prevention of ventricular premature beats, ventricular tachycardia, and ventricular fibrillation. The compound was well tolerated and neutral to circulatory variables. Other cardiovascular agents tested in this model were not, or were only partly, effective at doses showing marked cardiodepressive effects. CONCLUSIONS: HOE642 is a very selective NHE subtype 1 inhibitor showing cardioprotective and antiarrhythmic effects in ischaemic and reperfused hearts. Further development of well tolerated compounds like HOE642 could lead to a new therapeutic approach in clinical indications related to cardiac ischaemia and reperfusion.
Asunto(s)
Isquemia Miocárdica/metabolismo , Daño por Reperfusión Miocárdica/prevención & control , Intercambiadores de Sodio-Hidrógeno/antagonistas & inhibidores , Animales , Plaquetas/efectos de los fármacos , Plaquetas/metabolismo , Células Cultivadas , Relación Dosis-Respuesta a Droga , Eritrocitos/citología , Eritrocitos/efectos de los fármacos , Eritrocitos/metabolismo , Guanidinas/farmacología , Concentración de Iones de Hidrógeno , Masculino , Miocardio/citología , Miocardio/metabolismo , Perfusión , Conejos , Ratas , Ratas Sprague-Dawley , Intercambiadores de Sodio-Hidrógeno/metabolismo , Sulfonas/farmacologíaRESUMEN
A full-length cDNA encoding the broad bean lipoxygenase VfLOX1 was isolated from a nodule cDNA library. The VfLOX1 gene was strongly expressed in nodules, and only weakly in roots. VfLOX1 transcripts were localized in the nodule parenchyma and in the cells surrounding the root stele.
Asunto(s)
Fabaceae/enzimología , Fabaceae/genética , Genes de Plantas , Lipooxigenasa/genética , Plantas Medicinales , Secuencia de Aminoácidos , Secuencia de Bases , ADN Complementario/genética , ADN de Plantas/genética , Expresión Génica , Hibridación in Situ , Datos de Secuencia Molecular , Distribución TisularRESUMEN
1. Angiotensin converting enzyme (ACE)-inhibitors have been demonstrated to be effective in the treatment of cardiac hypertrophy when used in antihypertensive doses. The aim of our one year study with an ACE-inhibitor in rats was to separate local cardiac effects produced by a non-antihypertensive dose from those on systemic blood pressure when an antihypertensive dose was used. 2. Rats made hypertensive by aortic banding were subjected to chronic oral treatment for one year with an antihypertensive dose of the ACE inhibitor, ramipril 1 mg kg-1 daily, (RA 1 mg) or received a low dose of 10 micrograms kg-1 daily (RA 10 micrograms) which did not affect high blood pressure. 3. Chronic treatment with the ACE-inhibitor prevented left ventricular hypertrophy in the antihypertensive rats as did the low dose which had no effects on blood pressure. Similar effects were observed on myocardial fibrosis. Plasma ACE activity was inhibited in the RA 1 mg but not in the RA 10 micrograms group although conversion of angiotensin (Ang) I to Ang II in isolated aortic strips was suppressed in both treated groups. Plasma catecholamines were increased in the untreated control group, but treatment with either dose of ramipril normalized the values. The myocardial phosphocreatine to ATP ratio (an indicator of the energy state in the heart) was reduced in the vehicle control group whereas the hearts from treated animals showed a normal ratio comparable to hearts from sham-operated animals. 4. After one year, five animals were separated from each group, treatment withdrawn, and housed for additional six months. In the RA 1 mg group, blood pressure did not reach the value of the control vehicle group and surprisingly, left ventricular hypertrophy and myocardial fibrosis did not recur in animals during withdrawal of treatment.5. These data show that long term ACE inhibitor treatment with ramipril in antihypertensive and non-antihypertensive doses prevented cardiac hypertrophy and myocardial fibrosis. This protective effect was still present after 6 months treatment withdrawal.
Asunto(s)
Presión Sanguínea/efectos de los fármacos , Cardiomegalia/prevención & control , Fibrosis Endomiocárdica/prevención & control , Peptidil-Dipeptidasa A/sangre , Ramipril/farmacología , Adenosina Trifosfato/metabolismo , Angiotensinas/metabolismo , Animales , Aorta Torácica/química , Catecolaminas/sangre , GMP Cíclico/metabolismo , Hipertensión/tratamiento farmacológico , Masculino , Miocardio/metabolismo , Peptidil-Dipeptidasa A/análisis , Fosfocreatina/metabolismo , Radioinmunoensayo , Ramipril/administración & dosificación , Ratas , Ratas Endogámicas SHR , Ratas Sprague-DawleyRESUMEN
1. The benzoylguanidine derivative Hoe 694 ((3-methylsulphonyl-4- piperidino-benzoyl) guanidine methanesulphonate) was characterized as an inhibitor of Na+/H+ exchange in rabbit erythrocytes, rat platelets and bovine endothelial cells. The potency of the compound was slightly lower or comparable to ethylisopropyl amiloride (EIPA). 2. To investigate a possible cardioprotective role of the Na+/H+ exchange inhibitor Hoe 694, rat isolated working hearts were subjected to ischaemia and reperfusion. In these experiments all untreated hearts suffered ventricular fibrillation on reperfusion. Addition of 10(-7) M Hoe 694 to the perfusate almost abolished reperfusion arrhythmias in the rat isolated working hearts. 3. Hoe 694 reduced the release of lactate dehydrogenase (LDH) and creatine kinase (CK), which are indicators of cellular damage during ischaemia, into the venous effluent of the hearts by 60% and 54%, respectively. 4. The tissue content of glycogen at the end of the experiments was increased by 60% and the high energy phosphates ATP and creatine phosphate were increased by 240% and 270% respectively in the treated hearts as compared to control hearts. 5. Antiischaemic effects of the Na+/H+ exchange inhibitor, Hoe 694, were investigated in a second experiment in anaesthetized rats undergoing coronary artery ligation. In these animals, pretreatment with Hoe 694 caused a dose-dependent reduction of ventricular premature beats and ventricular tachycardia as well as a complete suppression of ventricular fibrillation down to doses of 0.1 mg kg-1, i.v. Blood pressure and heart rate remained unchanged. 6. We conclude that the new Na+/H+ exchange inhibitor, Hoe 694, shows cardioprotective and antiarrhythmic effects in ischaemia and reperfusion in rat isolated hearts and in anaesthetized rats. In view of the role which Na+/H+ exchange seems to play in the pathophysiology of cardiac ischaemia these effects could probably be attributed to Na+/H+ exchange inhibition.
Asunto(s)
Guanidinas/farmacología , Isquemia Miocárdica/tratamiento farmacológico , Potasio/metabolismo , Sodio/metabolismo , Sulfonas/farmacología , Adenosina Trifosfato/metabolismo , Amilorida/análogos & derivados , Amilorida/farmacología , Anestesia , Animales , Plaquetas/metabolismo , Bovinos , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/metabolismo , Membrana Eritrocítica/efectos de los fármacos , Membrana Eritrocítica/metabolismo , Femenino , Glucógeno/metabolismo , Guanidinas/uso terapéutico , Técnicas In Vitro , Intercambio Iónico , Masculino , Isquemia Miocárdica/fisiopatología , Fosfocreatina/metabolismo , Potasio/sangre , Conejos , Ratas , Ratas Sprague-Dawley , Ratas Wistar , Sodio/sangre , Sulfonas/uso terapéuticoRESUMEN
1. Hoe 140 (D-Arg-[Hyp3, Thi5, D-Tic7, Oic8]bradykinin) is a new bradykinin (BK)-antagonist. It was tested in several in vitro assays and compared with D-Arg-[Hyp2,Thi5,8,D-Phe7]BK. 2. In receptor binding studies in guinea-pig ileum preparations, Hoe 140 showed an IC50 of 1.07 x 10(-9) mol l-1 and a KI value of 7.98 x 10(-10) mol l-1. 3. In isolated organ preparations Hoe 140 and D-Arg-[Hyp2,Thi5,8, D-Phe7]BK inhibited bradykinin-induced contractions concentration dependently, with IC50-values in the guinea-pig ileum preparation of 1.1 x 10(-8) mol l-1 and 3 x 10(-5) mol l-1, respectively. pA2 values in this tissue were 8.42 and 6.18, respectively. In the rat uterus preparation the IC50 value was 4.9 x 10(-9) mol l-1 for Hoe 140. D-Arg-[Hyp2, Thi5,8, D-Phe7]BK showed an IC50 of 4.0 x 10(-6) mol l-1. The IC50 values in the guinea-pig isolated pulmonary artery were 5.4 x 10(-9) mol l-1 and 6.4 x 10(-6) mol l-1, respectively. In the rabbit aorta no inhibitory effects on Des-Arg9-BK induced contractions were observed. 4. In cultured bovine endothelial cells, Hoe 140 antagonized (IC50 = 10(-8) mol l-1) bradykinin-induced endothelium-derived relaxing factor (EDRF) release and the bradykinin-induced increase in cytosolic free calcium (IC50 = 10(-9) mol l-1). 5. Hoe 140 (10 -7mol I1) totally suppressed the bradykinin-induced (10 8 to 10- mol I') prostacyclin (PGI2) release from cultured endothelial cells of bovine aorta. D-Arg-[Hyp2, Thi5'8, D-Phe7]BK (10- 7 mol I1- ) showed a weaker antagonism. 6. Taken together these results show that Hoe 140 is a highly potent bradykinin antagonist. It was two to three orders of magnitude more potent than D-Arg-[Hyp2, Thi5 8, D-Phe7]BK.
Asunto(s)
Bradiquinina/análogos & derivados , Bradiquinina/antagonistas & inhibidores , Animales , Bradiquinina/farmacología , Calcio/metabolismo , Células Cultivadas , Endotelio Vascular/efectos de los fármacos , Endotelio Vascular/metabolismo , Epoprostenol/metabolismo , Femenino , Cobayas , Íleon/efectos de los fármacos , Íleon/fisiología , Técnicas In Vitro , Masculino , Contracción Muscular/efectos de los fármacos , Óxido Nítrico/metabolismo , Arteria Pulmonar/efectos de los fármacos , Arteria Pulmonar/fisiología , Conejos , Ratas , Ratas WistarRESUMEN
1. The potency, duration of action and tolerability of Hoe 140, a novel and highly potent bradykinin (BK) antagonist in vitro, has been tested in different in vivo models and compared with the well-known BK antagonist D-Arg-[Hyp2, Thi5,8, D-Phe7]BK. 2. Hoe 140 is highly potent and long acting in inhibiting BK-induced hypotensive responses in the rat. Four hours after s.c. administration of 20 nmol kg-1, inhibition still amounted to 60% whereas the effect of 200 nmol kg-1 of D-Arg-[Hyp2, Thi5,8, D-Phe7]BK was not significant. 3. BK-induced bronchoconstriction in guinea-pigs was strongly inhibited by Hoe 140. The magnitude and duration of inhibition confirmed the findings obtained in the blood pressure experiments in the rat. 4. Carrageenin-induced inflammatory oedema of the rat paw was considerably inhibited at i.v. doses between 0.1 and 1 mg kg-1. 5. In conscious dogs, intravenous doses of 0.01 and 0.1 mg kg-1 of Hoe 140 and D-Arg-[Hyp2, Thi5,8, D-Phe7]BK were well tolerated. At doses of 1 mg kg-1 adverse effects occurred that were attributed to the residual BK agonistic activity of both compounds. 6. Hoe 140 has been shown to be a highly potent and long acting BK antagonist in vivo in different animal species and models. This makes it appropriate to investigate further the physiological and pathophysiological role of BK.
Asunto(s)
Bradiquinina/análogos & derivados , Bradiquinina/antagonistas & inhibidores , Animales , Presión Sanguínea/efectos de los fármacos , Bradiquinina/farmacología , Broncoconstricción/efectos de los fármacos , Perros , Edema/prevención & control , Femenino , Cobayas , Frecuencia Cardíaca/efectos de los fármacos , Masculino , Ratas , Ratas Sprague-DawleyRESUMEN
Evidence for angiotensin-converting enzyme (ACE) on isolated human glomeruli was furnished by specific binding of tritium-labeled ramiprilat, a potent inhibitor of ACE. 3H-ramiprilat bound to isolated glomeruli, depending on time and temperature displaying a KD of 3.8 nmol/l and a Bmax of 853 fmol/mg protein. Specific binding represented more than 90% of total binding. Dissociation occurred rapidly after dilution of the sample with incubation buffer or after addition of an excess of unlabeled inhibitor. Binding of 3H-ramiprilat was also inhibited by increasing concentrations of enalaprilat, another ACE-inhibitor or by preincubation of the glomeruli with polyclonal antibodies against ACE. ACE is a zinc-containing enzyme. Addition of EGTA to the assay, which chelates zinc ions, completely inhibited binding. This inhibitory effect of EGTA was reversed by divalent Zn2+ and Ca2+ ions but not by magnesium. Binding of 3H-ramiprilat to isolated glomeruli was maximal when the pH of the assay medium was brought to pH 8. In conclusion, the binding of 3H-ramiprilat to isolated human glomeruli is specific and resembles the characteristics which have been found earlier for enzyme activity of ACE. Thus, binding of 3H-ramiprilat to isolated glomeruli can be assumed to be directed to ACE.
Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/metabolismo , Glomérulos Renales/metabolismo , Peptidil-Dipeptidasa A/metabolismo , Pirroles/metabolismo , Ramipril/análogos & derivados , Ribonucleósidos/farmacología , Unión Competitiva , Cationes Bivalentes/farmacología , Ácido Egtácico/farmacología , Humanos , Técnicas In Vitro , Unión Proteica , Ribonucleósidos/metabolismo , Zinc/farmacologíaRESUMEN
The smooth muscle relaxant effects of the novel potassium channel opener, HOE 234, were investigated in guinea pig airways and compared with those of lemakalim (BRL 38227). Both agents evoked concentration-related reduction in spontaneous tracheal tone or in the tone induced by histamine, prostaglandin E2 or carbachol. HOE 234 was more potent, particularly against carbachol, and was considerably longer acting than lemakalim in a wash-out experiment. On testing for preventive efficacy against histamine-induced bronchoconstriction in anaesthetized animals a dose-related decrease of pulmonary resistance (RL) was observed. HOE 234 given either intravenously (i.v.) or by inhalation was longer acting and 3 and 6 times more potent than lemakalim. Administration of 30 micrograms/kg i.v. HOE 234 during continuous bronchoconstriction maintained by infusion of histamine decreased RL for more than 20 min whereas the effect of 100 micrograms/kg i.v. lemakalin disappeared within 4 min. These results show that HOE 234 is effective against contractile response induced by asthma mediators in guinea pig airways and compares favourably with lemakalim. Moreover it acts on acute existing bronchospasm and therefore has the potential to act against asthma attacks.
Asunto(s)
Broncodilatadores/farmacología , Cromanos/farmacología , Canales de Potasio/efectos de los fármacos , Pirrolidinas/farmacología , Tráquea/efectos de los fármacos , Animales , Benzopiranos/farmacología , Broncoconstrictores/farmacología , Carbacol/farmacología , Cromakalim , Dinoprostona/farmacología , Femenino , Cobayas , Histamina/farmacología , Técnicas In Vitro , Masculino , Relajación Muscular/efectos de los fármacos , Músculo Liso/efectos de los fármacos , Pirroles/farmacologíaRESUMEN
It has been argued that activation of KATP channels in the sarcolemmal membrane of heart muscle cells during ischemia provides an endogenous cardioprotective mechanism. In order to test whether the novel cardioselective KATP channel blocker HMR 1098 affects cardiac function during ischemia, experiments were performed in rat hearts during ischemia and reperfusion. Isolated perfused working rat hearts were subjected to 30 min of low-flow ischemia in which the coronary flow was reduced to 10% of its control value, followed by 30-min reperfusion. In the first set of experiments the hearts were electrically paced at 5 Hz throughout the entire protocol. At the end of the 30-min ischemic period the aortic flow had fallen to 44 +/- 2% (n=8) of its nonischemic value in vehicle-treated hearts, whereas in the presence of 0.3 micromol/l and 3 micromol/l HMR 1098 it had fallen to 29 +/- 7% (n=5, not significant) and 8 +/- 2% (n=12, P<0.05), respectively. Glibenclamide (3 micromol/l) reduced the aortic flow to 9.5 +/- 7% (n=4, P<0.05). In control hearts the QT interval in the electrocardiogram shortened from 63 +/- 6 ms to 36 +/- 4 ms (n=10, P<0.05) within 4-6 min of low-flow ischemia. This shortening was completely prevented by 3 micromol/l HMR 1098 (60 +/- 5 ms before ischemia, 67 +/- 6 ms during ischemia, n=9, not significant). When rat hearts were not paced, the heart rate fell spontaneously during ischemia, and HMR 1,098 (3 micromol/l) caused only a slight, statistically non-significant reduction in aortic flow during the ischemic period. In order to investigate whether HMR 1098 shows cardiodepressant effects in a more pathophysiological model, the left descending coronary artery was occluded for 30 min followed by reperfusion for 60 min in anesthetized rats. Treatment with HMR 1098 (10 mg/kg i.v.) had no statistically significant effects on mean arterial blood pressure and heart rate during the control, ischemia and reperfusion periods. At the end of the reperfusion period, aortic blood flow was slightly reduced by HMR 1098, without reaching statistical significance (two-way analysis of ANOVA, P=0.15). Myocardial infarct size as a percentage of area at risk was not affected by HMR 1098 (vehicle: 75 +/- 3%, HMR 1098: 72 +/- 2%, n=7 in each group). In conclusion, cardiodepressant effects of HMR 1098 were observed only in isolated perfused working rat hearts which were continuously paced during global low-flow ischemia. In the model of anesthetized rats subjected to regional ischemia, HMR 1098 had no significant effect on cardiac function or infarct size.
Asunto(s)
Benzamidas/farmacología , Corazón/efectos de los fármacos , Isquemia Miocárdica/fisiopatología , Bloqueadores de los Canales de Potasio/farmacología , Potasio/metabolismo , Tiourea/análogos & derivados , Anestesia , Animales , Antiarrítmicos/farmacología , Benzamidas/administración & dosificación , Gliburida/farmacología , Corazón/fisiopatología , Hemodinámica/efectos de los fármacos , Técnicas In Vitro , Masculino , Modelos Animales , Contracción Miocárdica/efectos de los fármacos , Infarto del Miocardio , Reperfusión Miocárdica , Ratas , Ratas Wistar , Sulfonamidas/farmacología , Tiourea/farmacologíaRESUMEN
In order to elucidate the mode of action of tetanus toxin, particles from rat forebrain were preloaded with tritiated GABA or D-aspartate, pre-incubated with tetanus toxin and then depolarized with K+, either in a batch procedure or by superfusion. The toxin depresses, but does not abolish, the evoked outflow of both amino acids in either system. Omission of Ca2+ decreases the outflow in the batch procedure by about 40%. The remaining outflow of either amino acid is insensitive to tetanus toxin, whereas the Ca2+ dependent outflow is completely inhibited. Antitoxin neutralizes the toxin but does not reverse its in vitro effects, once manifest. The toxin effects increase with time and temperature of pre-incubation. Pretreatment of the particles with V. cholerae neuraminidase, which is known to convert the long-chain gangliosides quantitatively into GM1, does not decrease the sensitivity to tetanus toxin. Besides particles from rat brain, those from chicken, but not those from frog brain, are toxin-sensitive when tested for GABA outflow in the batch procedure. Frog brain does not yield the typical ganglioside pattern, and also does not measurably bind 125I-tetanus toxin. The homoexchange diffusion of GABA, but not of D-aspartate, is slightly facilitated by tetanus toxin. We confirmed that tetanus toxin slightly inhibits the uptake of GABA, whereas that of D-aspartate is not measurably influenced. The accumulation, driven by a Na+/K+ gradient, of GABA into membrane vesicles from rat cortex is not affected by tetanus toxin. The present data support the hypothesis that tetanus toxin influences a process involved in the outflow of many transmitters, both excitatory and inhibitory.
Asunto(s)
Ácido Aspártico/metabolismo , Corteza Cerebral/efectos de los fármacos , Toxina Tetánica/toxicidad , Ácido gamma-Aminobutírico/metabolismo , Animales , Calcio/fisiología , Membrana Celular/metabolismo , Corteza Cerebral/análisis , Corteza Cerebral/metabolismo , Pollos , Femenino , Gangliósidos/análisis , Técnicas In Vitro , Norepinefrina/metabolismo , Ranidae , Ratas , Ratas Endogámicas , Especificidad de la Especie , TemperaturaRESUMEN
In isolated ischaemic rat hearts, endothelin induced a short transient increase, followed by a lasting decrease in coronary flow and an increase in the left ventricular dp/dt max in a concentration-dependent manner. Both enzyme activities and lactate output were increased in the venous effluent. Myocardial tissue levels of glycogen, ATP and creatine phosphate were reduced. Endothelin aggravated post-ischaemic reperfusion arrhythmias. Perfusion with ramiprilat and bradykinin increased coronary flow and left ventricular dp/dt max and reduced reperfusion arrhythmias; enzyme activities and lactate output were significantly reduced and in the myocardial tissue glycogen and energy-rich phosphates were preserved. In comparison, indomethacin prolonged reperfusion arrhythmias, decreased coronary flow and increased the enzyme activities with no changes in myocardial metabolism. When ramiprilat and bradykinin were combined with endothelin, reperfusion arrhythmias and the enzyme activities were reduced but the decrease in coronary flow could not be fully blocked. Indomethacin aggravated the endothelin-induced coronary flow reduction, enzyme release and reperfusion arrhythmias but had no effects on the other parameters.
Asunto(s)
Inhibidores de la Enzima Convertidora de Angiotensina/uso terapéutico , Bradiquinina/uso terapéutico , Endotelio Vascular/fisiología , Indometacina/uso terapéutico , Daño por Reperfusión Miocárdica/tratamiento farmacológico , Péptidos/uso terapéutico , Pirroles/uso terapéutico , Ramipril/análogos & derivados , Vasoconstrictores/uso terapéutico , Animales , Evaluación Preclínica de Medicamentos , Interacciones Farmacológicas , Quimioterapia Combinada , Endotelinas , Femenino , Técnicas In Vitro , Masculino , Reperfusión Miocárdica/métodos , Daño por Reperfusión Miocárdica/fisiopatología , Ratas , Ratas EndogámicasRESUMEN
We have demonstrated an interaction between the effects of amiloride and atrial natriuretic factor (ANF) on the vascular system. In precontracted rabbit aortic strips the relaxant effect of a combination of ANF (10(-10) mol/l) and amiloride (10(-5) mol/l) was synergistic. The production of cyclic (c)GMP, which parallels ANF-induced relaxation of the strips, was not affected by amiloride alone up to 10(-3) mol/l, but was concentration-dependently increased in the presence of 10(-8) mol/l ANF. In spontaneously hypertensive rats (SHR) ANF-induced decreases in blood pressure were potentiated by amiloride. Binding experiments revealed an interaction between amiloride and ANF at the receptor level; binding of labelled ANF to aortic tissue was increased by amiloride but decreased by ATP. These data show that amiloride and ATP influence a mechanism that determines the sensitivity of vessels to ANF and this interaction occurs both at receptor level and at the level of transduction.
Asunto(s)
Amilorida/farmacología , Aorta/efectos de los fármacos , Factor Natriurético Atrial/farmacología , Vasoconstricción/efectos de los fármacos , Adenosina Trifosfato/farmacología , Animales , GMP Cíclico/metabolismo , Cobayas , Técnicas In Vitro , Potasio/farmacología , Conejos , Ratas , Ratas EndogámicasRESUMEN
The interaction between atrial natriuretic factor [synthetic human ANF-(103-126)] and angiotensin II (Ang II) and its influence on reperfusion arrhythmias, cardiodynamics, enzyme loss and metabolic changes were investigated in isolated ischaemic working rat hearts. Acute regional myocardial ischaemia was induced by coronary artery occlusion which was associated with ventricular fibrillation. Perfusion with 1 X 10(-9) mol/l Ang II markedly aggravated these arrhythmias. Perfusion with 1 X 10(-7) mol/l ANF, in contrast, gave protection against ventricular fibrillation and prevented Ang II-induced aggravation of ventricular fibrillation. Atrial natriuretic factor improved cardiodynamics, in particular, during reperfusion, whereas Ang II impaired cardiodynamics and increased the release of creatine kinase and lactate dehydrogenase. These adverse effects of Ang II were absent when ANF was simultaneously perfused. Compared with control hearts, myocardial tissue levels of glycogen, ATP and creatine phosphate were increased in hearts perfused with either ANF or ANF plus Ang II, whereas lactate levels decreased. Perfusion with Ang II alone led to deterioration in these metabolic parameters. These results in isolated working rat hearts suggest that ANF protects against the consequences of ischaemia and reperfusion and that functional antagonism between ANF and Ang II may contribute to this.
Asunto(s)
Angiotensina II/antagonistas & inhibidores , Factor Natriurético Atrial/farmacología , Enfermedad Coronaria/fisiopatología , Daño por Reperfusión Miocárdica/fisiopatología , Animales , Arritmias Cardíacas/etiología , Circulación Coronaria/efectos de los fármacos , Ratas , Ratas Endogámicas , Fibrilación Ventricular/etiologíaAsunto(s)
Enfermedades Cardiovasculares/tratamiento farmacológico , Intercambiadores de Sodio-Hidrógeno/antagonistas & inhibidores , Animales , Calcio/metabolismo , Cobayas , Concentración de Iones de Hidrógeno , Isquemia Miocárdica/tratamiento farmacológico , Daño por Reperfusión Miocárdica/tratamiento farmacológico , Miocardio/metabolismo , Ratas , Sodio/metabolismoRESUMEN
The characterization of various ion transport systems has led to a better understanding of the effects, which seem to take part in the impairment of ischemic and reperfused cardiac tissue. This review discusses the role of the Na+/H+ exchange system in the pathophysiology of ischemia and reperfusion and the beneficial effects of its inhibition. At the onset of ischemia intracellular pH (pHi) decreases due to anaerobic metabolism and ATP hydrolysis, leading to an activation of Na+/H+ exchange. This in turn increases intracellular Na+ (Na+i) and activates Na+/K+ ATPase, with a consecutive increase of energy consumption. Since cellular Na+ and Ca++ transport are coupled by the Na+/Ca++ exchange system, which depends on the Na+ gradient, the high Na+i leads to increased intracellular Ca++ (Ca++i). After a certain period, Na+/H+ exchange is inactivated by a decrease of extracellular pH. In case of reperfusion the acid extracellular fluid is washed out, which reactivates Na+/H+ exchange, leading to an unfavourably fast restoration of pHi and a second time to Na+ and Ca++i overflow. High Ca++i is assumed to be one of the main reasons for ischemic and reperfusion injury, like arrhythmias, myocardial contracture, stunning and necrosis. It seems that the inhibition of Na+/H+ exchange can interrupt this process at an early phase and prevent or delay the consequences of ischemia and reperfusion as demonstrated by numerous investigators.
Asunto(s)
Isquemia Miocárdica/metabolismo , Reperfusión Miocárdica , Intercambiadores de Sodio-Hidrógeno/antagonistas & inhibidores , Intercambiadores de Sodio-Hidrógeno/metabolismo , Animales , Circulación Coronaria , Hipoxia/fisiopatología , Isquemia Miocárdica/fisiopatología , Intercambiadores de Sodio-Hidrógeno/fisiologíaRESUMEN
125I-Tetanus toxin is bound by basolateral membranes from rabbit kidneys. Fixation is specific, as it is minimally inhibited by the nonbinding (fragment B) moiety of tetanus toxin, whereas the binding moiety (fragment C) is equivalent to the native toxin in inhibiting fixation. Competition is also pronounced with mildly toxoided toxin. Association and dissociation of 125I-toxin are delayed in kidney when compared to brain membranes. The binding sites in kidney membranes are partially sensitive to neuraminidase and resist heating to 56 degrees C, in contrast to those in brain membranes which are very sensitive to both treatments. The binding sites of the two preparations can be discriminated further by variation of the ionic environment. Sodium dodecyl sulfate-disc gel electrophoresis followed by transfer to nitrocellulose, and TLC with consecutive overlay indicate that tetanus toxin exclusively binds to long-chain gangliosides from rat brain. Binding sites in kidney membranes from rabbits and rats can be made visible by the overlay technique. They are apparently heterogeneous and more hydrophobic. We conclude that rabbit kidney contains binding sites for tetanus toxin which resemble gangliosides but differ from the major gangliosides in brain both chemically and with respect to their interaction with tetanus toxin.
Asunto(s)
Encéfalo/metabolismo , Riñón/metabolismo , Toxina Tetánica/metabolismo , Animales , Sitios de Unión/efectos de los fármacos , Unión Competitiva , Membrana Celular/metabolismo , Colodión , Electroforesis en Gel de Poliacrilamida , Gangliósidos/metabolismo , Calor , Neuraminidasa/farmacología , Concentración Osmolar , Fragmentos de Péptidos/metabolismo , Conejos , RatasRESUMEN
Recent data demonstrated effects of bradykinin (BK) in the isolated perfused rat heart which could be blocked by BK antagonists. However, so far BK receptors in heart tissue have not been characterized. To search for BK receptors in rat hearts iodinated D-Arg[Hyp3,Thi5,D-Tic,Oic8]BK (Hoe 140) was used as a ligand for binding due to its high affinity and to its resistance to degradation. The labeled antagonist bound well to membranes prepared from rat ileum and could be displaced by the unlabeled antagonist as well as by BK and T-kinin in a concentration dependent manner. However, there was no specific binding detectable when membranes from rat left cardiac ventricle were used. To assure integrity of at least one other receptor in these membranes, binding of 3H-methylscopolamine and its displacement by the respective cold ligand was demonstrated. To rule out an occupation of the BK receptors by endogenous formed BK, the tissue was treated with an acidic buffer with high ionic strength to remove surface bound BK. However, this treatment did not unmask any specific binding for the BK antagonist. In view of the possibility that the structure of the labeled antagonist prevented its binding, experiments were carried out using tritiated BK itself. These experiments also failed to demonstrate specific binding sites which indicate that the structural aspects of Hoe 140 are probably not interfering in binding of the antagonist, especially since it binds to ileum. It is concluded, that there are too few binding sites for BK in the rat heart homogenate for ordinary binding studies.(ABSTRACT TRUNCATED AT 250 WORDS)
Asunto(s)
Bradiquinina/análogos & derivados , Bradiquinina/metabolismo , Miocardio/metabolismo , Receptores de Neurotransmisores/análisis , Animales , Sitios de Unión , Unión Competitiva , Membrana Celular/metabolismo , Femenino , Íleon/metabolismo , Cinética , Músculo Liso/metabolismo , N-Metilescopolamina , Parasimpatolíticos/metabolismo , Ratas , Ratas Sprague-Dawley , Receptores de Bradiquinina , Receptores de Neurotransmisores/metabolismo , Derivados de Escopolamina/metabolismoRESUMEN
The effects of the novel 1,4-dihydropyridine Bay K 8644 [methyl-1,4-dihydro-2,6-dimethyl-3-nitro-4-(2-trifluoromethylphenyl)-pyridine- 5-carboxylate] on the release of [3H]noradrenaline in cultured PC 12 cells were investigated. K+ in a concentration-dependent manner evoked 3H-transmitter release with an EC50 of 50-56 mM. Bay K 8644 at 30 nM potentiated the K+-evoked [3H]noradrenaline release; however, in the absence of calcium neither K+ evoked nor Bay K 8644 enhanced [3H]noradrenaline release. At a K+ concentration of 25 mM, Bay K 8644 stimulated [3H]noradrenaline release fivefold, with an EC50 of 10 nM, and 100 nM of the calcium channel blocker nitrendipine shifted the concentration response curve of Bay K 8644 to the right in an apparently competitive fashion. Nitrendipine blocked the Bay K 8644-potentiated release with an EC50 of 700 nM in the presence of 500 nM Bay K 8644. [3H]Nitrendipine bound to a saturable population of binding sites on PC 12 cell membranes with a Bmax of 180 fmol X mg-1 of membrane protein and a KD of 0.9 nM. Bay K 8644 inhibited [3H]nitrendipine binding with a Ki of 16 nM. It is concluded that Bay K 8644 binds to, and stabilizes, the open state of calcium channels and thus acts as a "calcium agonist" to mediate calcium-dependent cellular events such as catecholamine release from PC 12 cells.
Asunto(s)
Neoplasias de las Glándulas Suprarrenales/metabolismo , Calcio/metabolismo , Nifedipino/análogos & derivados , Norepinefrina/metabolismo , Feocromocitoma/metabolismo , Ácido 3-piridinacarboxílico, 1,4-dihidro-2,6-dimetil-5-nitro-4-(2-(trifluorometil)fenil)-, Éster Metílico , Animales , Relación Dosis-Respuesta a Droga , Cinética , Nifedipino/metabolismo , Nifedipino/farmacología , Nitrendipino , Potasio/farmacología , RatasRESUMEN
Studies are presented which indicate that T-kininogen, the acute phase kininogen of the rat, could be a healing protein because of its properties as a cysteine protease inhibitor. Evidence is also presented that mRNA of T-kininogen synthesis may be a function of interleukin 6 production. A regulatory mechanism is postulated by which SH cofactors could determine if T-kinin is released or whether the T-kininogen molecule would remain intact. Evidence is also presented that T-kinin acts through kinin B2 receptors. No specific binding of bradykinin or T-kinin could be detected in rat heart preparations.